异动解读 | 美国血液技术财报超预期 盘前股价大涨6%

异动解读
07 Nov 2024

美国血液技术(HAE)公司周二盘前股价大涨6.19%,投资者对其最新财报业绩表现反应热烈。

美国血液技术公司公布的截至9月30日的季度调整后每股收益为1.12美元,超出分析师预期的1.07美元。该公司本季度营收同比增长8.6%至3.4551亿美元,但略低于分析师3.4265亿美元的预期区间。

尽管营收略有失算,但美国血液技术依然交出了可观的业绩。分析师普遍看好该公司长期前景,给予"买入"的评级。分析师认为,公司在医疗设备、用品和分销领域具有良好的发展潜力,预计其未来12个月股价目标中位数为113.5美元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10